$CNXC

Concentrix declares $0.37 dividend (NASDAQ:CNXC)

Concentrix (CNXC) declared a $0.37 per share quarterly dividend, maintaining the previous rate. The forward yield is 5.95%. The dividend is payable on November 3 to shareholders of record on October 23. The company also expects new business revenues to exceed $6 billion in 2027 and targets 2.2x net leverage. CNXC reported Q3 2026 Non-GAAP EPS of $2.92, beating estimates by $0.22, but revenue of $2.45B missed by $30M.

Original reporting
Published Sep 30, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CNXC
Neutral
high confidence
Mentioned
$CNXC
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CNXCNeutralMed
01

Why it matters

The dividend announcement adds a new data point for income‑focused investors and may cause a short‑term price bump.

02

Market read

A new dividend declaration is a primary corporate action that can influence short‑term trading decisions for CNXC.

03

What to watch

The dividend is unchanged from prior periods, so the market may have already priced it in.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Concentrix (NASDAQ:CNXC) is a business‑process outsourcing firm that recently reported Q3 earnings and provided guidance for 2027.

Company-level read

Ticker impact

$CNXCNeutralHigh confidence
Context

Concentrix announced a quarterly dividend of $0.37 per share, a new corporate action disclosed in this article.

Expected impact

modest upside as the market prices in the dividend yield

Evidence & confidence

Dividends typically generate a small positive price reaction, especially when the yield is attractive relative to peers.

Market effects

May slightly improve sentiment toward the business‑services sector as dividend yields become more competitive.

Limited to U.S. equity markets where CNXC trades.

Minimal global impact; primarily a company‑specific event.

Counterpoint

Investors could view the modest dividend as a signal that growth prospects are limited, prompting a sell‑off.

Key entities

  • Concentrix

    U.S.-listed business‑process outsourcing firm.

Related articles

$CNXCHighAI 8/10

Concentrix earnings analysis: questions answered and next catalysts

Concentrix Corp (CNXC) reported Q3 earnings with a $0.21 EPS beat ($2.92) but a $30M revenue miss ($2.45B vs. $2.48B est). Shares initially dropped 9.77% before recovering 3.12%. Management highlighted AI-driven revenue growth (50% of total) and cash flow strength ($218M), but revenue declines due to specific client exits and offshoring. The dividend was raised to $0.37/share. Growth is expected to return in 2028, with key catalysts including Q4 earnings and debt paydown milestones.

$CNXCMedAI 8/10

Why Concentrix Stock Ended Up Moving Higher Today

Concentrix (CNXC) reported fiscal Q3 revenue below estimates due to client shifts, but earnings beat expectations. CEO Christopher Caldwell attributed the shortfall to client preferences, not customer loss. The stock initially dropped but recovered, up 3% by midday. Analysts' average price target is $33.50, over 30% above current levels.

$LQDAMed

Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

$CNXCLow

Why Concentrix (CNXC) Stock Is Up Today

Concentrix (CNXC) stock rose 4% after reporting a Q3 net loss of $988.1M, driven by a $1.5B goodwill impairment charge. Revenue fell 1.2% YoY to $2.45B, missing estimates. Adjusted EPS was $2.92. The company cited AI deployments and client decisions for the decline. Shares later cooled to $25.73, up 1%.